Olivia A. Herrmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivia A. Herrmann has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alisyn R. Bourque
Bioengineering, Georgia Institute of Technology, Atlanta, USA
1 shared publication- Elisa Schrader Echeverri
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, USA
1 shared publication Isabel A. Panicker
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, USA
1 shared publication- James E. Dahlman
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA
1 shared publication Johana C. Arboleda
Robert P. Apkarian Integrated Electron Microscopy Core, Emory University, Atlanta, USA
1 shared publicationJohn F. McDonald
School of Biological Sciences, Georgia Institute of Technology, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 184
Tumor agnostic drug delivery with dynamic nanohydrogels
RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.
- 7 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 184
Open AccessTumor agnostic drug delivery with dynamic nanohydrogels
RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.